OR WAIT null SECS
TrialAssure announced that it is collaborating with MMS on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development.
The primary focus of this collaboration is to utilize AI to generate text specifically tailored for creating plain language summary (PLS) documents. These documents help clinical researchers effectively communicate their findings with patients, families, and the public by presenting the results in a manner that is easily understandable to the average reader.
This initiative will allow the companies to complete an initial draft of a medical writing document more efficiently. Instead of writing sections from scratch, TrialAssure Link will produce the first draft for the medical writer to review and update.
“Our AI solutions experts and SMEs with extensive experience in medical writing and clinical trial-related documents are working together hand-in-hand to develop this new technology that will help shape the future of the pharmaceutical industry,” said Zach Weingarden, director of product solutions, TrialAssure. “The possibilities of AI in this industry are endless, and we are exploring additional use cases that target different aspects of the clinical trial and related documents at various stages.”
TrialAssure Announces AI Generative Text Partnership with Top Clinical Research Organization MMS on New Medical Writing Initiative. (2023, August 3). TrialAssure.